Literature DB >> 32676141

RAF Kinases in Cancer: A Moving Target and Degradation Therapy.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2020        PMID： 32676141      PMCID： PMC7356375          DOI： 10.1021/acsmedchemlett.0c00299

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  RAF kinase dimerization: implications for drug discovery and clinical outcomes.

Authors:  Tilman Brummer; Campbell McInnes
Journal:  Oncogene       Date:  2020-04-08       Impact factor: 9.867

Review 2.  Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.

Authors:  Nalan Akgul Babacan; Zeynep Eroglu
Journal:  Curr Oncol Rep       Date:  2020-03-20       Impact factor: 5.075

Review 3.  Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.

Authors:  Mitchell I Parker; Anna S Nikonova; Danlin Sun; Erica A Golemis
Journal:  Cell Signal       Date:  2019-12-09       Impact factor: 4.315

4.  Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors.

Authors:  Yanan Li; Qingrong Dong; Ting Mei; Meichen Zheng; Ramasamy Raj Kumar; Bin Yu; Chunsheng Wu; Hui Zhang; Feifei An
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.